Identification and quantitation of fexofenadine hydrochloride in model oral drops

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Relevance. Fexofenadine hydrochloride is a representative of the III generation of histamine H1 receptor blockers, therefore, it is not characterized by the disadvantages of antihistamines, such as: suppression of the central nervous system, cardiotoxic effect, headache, impaired coordination of movements, photosensitivity. Analysis of fexofenadine hydrochloride was performed using UV spectroscopy.

The purpose of the study – development of a new analytical method for the qualitative and quantitative identification of fixofenadine in drops for internal use.

Material and methods. The study used: fexofenadine, sodium hydroxide, water for injection, UV spectrophotometer type SF-104.

Results and conclusions. A method for the qualitative and quantitative determination of fexofenadine hydrochloride in model drops for internal use by the SPS method has been proposed. This method meets the requirements of OFS 1.1.0012.15 Validation of analytical methods, in terms of indicators: linearity and analytical area, correctness, precision.

全文:

受限制的访问

作者简介

Abdulhadi Bakri

Belgorod National Research University

编辑信件的主要联系方式.
Email: EZhilyakova@bsu.edu.ru

Post-graduate Student, Department of Pharmaceutical Technology, Faculty of Pharmacy

俄罗斯联邦, Belgorod

E. Zhilyakova

Belgorod National Research University

Email: EZhilyakova@bsu.edu.ru

Dr.Sc. (Pharm.), Professor, Department of Pharmaceutical Technology, Faculty of Pharmacy

俄罗斯联邦, Belgorod

Ghadeer Balloul

Belgorod National Research University

Email: ghadeerballoul@gmail.com

Master, Department Pharmaceutical and Chemical Technology

俄罗斯联邦, Belgorod

Abdullah Yousif

Belgorod National Research University

Email: EZhilyakova@bsu.edu.ru

Post-graduate Student, Department of Pharmaceutical Technology, Faculty of Pharmacy

俄罗斯联邦, Belgorod

A. Taran

Belgorod National Research University

Email: EZhilyakova@bsu.edu.ru

Ph.D (Pharm.), Senior Lecturer, Department of Pharmaceutical Technology

俄罗斯联邦, Belgorod

参考

  1. Fouad M., Ragab M. Effectiveness and safety of fexofenadine in chronic idiopathic urticaria − open-label noncomparative study in daily practice. The Egyptian Journal of Dermatology and Venerology. 2017; 2(37): 43–48.
  2. Horn M.M., Nguyen A.L., Bielory L. Allergic conjunctivitis and dry eye syndrome. Ann Allergy Asthma Immunol. – 2012. 108 (3): P. 163-166.
  3. Van Cauwenberge P., Juniper E.F. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy. 2000 Jun; 30(6): 891–899. doi: 10.1046/j.1365-2222.2000.00914.x.
  4. Howarth P.H., Stern M.A., Roi L., Reynolds R., Bousquet J. Double-blind, placebocontrolled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol. 1999 Nov; 104(5): 927–933. doi: 10.1016/s0091-6749(99)70070-9. PMID: 10550734.
  5. Gross G.N., Ganster K., Meeves S., Liao Y., Georges G.C. A double-blind, randomized comparison of fexofenadine 180 mg versus cetirizine 10 mg: effect on instantaneous symptom score at the 24th hour. Ann Allergy Asthma Immunol. 2003; 90: 125.
  6. Hampel F., Ratner P., Mansfield L., Meeves S., Liao Y., Georges G. Fexofenadine hydrochloride, 180 mg, exhibits equivalent efficacy to cetirizine, 10 mg, with less drowsiness in patients with moderate-to-severe seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003; 91: 354–361.
  7. Sareen S., Mathew G., Joseph L. Improvement in solubility of poor water-soluble drugs by solid dispersion. Int. J. Pharm. Investig. 2012; 2(1): 12–17.
  8. Schoenwald R.D. Ocular pharmacokinetics. Textbook of Ocular Pharmacology; Lippincott-Raven: Philadelphia, PA, USA. 1997: 119–138.
  9. CH Topic Q 2 (R1) Validation of Analytical Procedures. Text and Methodology: June 1995, CPMP/ICH/381/95 / European Medicines Agency. London. 2006. 15 p. [Electronic resource]. Mode of access: http://www.ema.europa.eu/docs/en_ GB/document_library/Scientific_guideline/2009/09/WC5000 02662.pdf.
  10. Gosudarstvennoj farmakopei Rossijskoj Federacii, OFS.1.1.0012.15 Validaciya analiticheskih metodik [In Russia] (Государственной фармакопеи Российской Федера-ции, ОФС.1.1.0012.15 Валидация аналитических методик).
  11. Uing G. Instrumental'nye metody analiza. Moskva: Mir, 1989. 608 s. [In Russia] (Юинг Г. Инструментальные методы анализа. Москва: Мир, 1989. 608 с.)
  12. Yakusheva E.N., Chernyh I.V., Shchul'kin A.V., Gacanoga M.V. Razrabotka VEZHKH-metodiki kolichestvennogo analiza feksofenadina v plazme krovi. Farmakokinetika i farmakodinamika. 2017; 2: 35–38. [In Russia] (Якушева Е.Н., Черных И.В., Щулькин А.В., Гацанога М.В. Разра-ботка ВЭЖХ-методики количественного анализа фексо-фенадина в плазме крови. Фармакокинетика и фармакодинамика. 2017; 2: 35–38.)
  13. Krishnan S.K., Veerasamy R., Thiyagu R., Dharamsi A., Raja M. Spectrophotometric Determination of Fexofenadine hydrochloride. Indian Journal of Pharmaceutical Sciences. 2006; 68(6): 841–842.
  14. Rajan V. UV Spectrophotometric Estimation of Fexofenadine hydrochloride by First Order Derivative and Area under Curve Methods in Bulk and Pharmaceutical Dosage Form. Der Pharmacia Lettre. 2016; 8(10): 95–101.
  15. British Pharmacopoeia 2009; Volume I and II; 2494–2500. 15. XIV.

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig 1. Curve spectrum of fexofenadine hydrochloride

下载 (249KB)
索引源数据
3. Fig. 2. Graphical representation of linearity: the relationship between the analytical signal (absorbance of fexofenadine) and the concentration of pure fexofenadine

下载 (28KB)
索引源数据

版权所有 © Bakri A.A., Zhilyakova E.T., Balloul G., Yousif A.Y., Taran A.V., 2023
##common.cookie##